Loading stock data…
AC Immune SA (ACIU)
$2.23-0.01 (-0.45%)
Market ClosedLast close Jul 24
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AC Immune SA in the Healthcare sector is trading at $2.23 with a market capitalization of $238M. Wall Street consensus targets $8.51 (4 analysts), implying a +281.5% move over the next 12 months. The stock is currently near its 52-week low of $2.03, remaining 24.1% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +281.5% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 34) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $1.12M↑ | $338,000↓ | $939,000↓ | $1.31M↑ | $990,000 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$14.79M↓ | -$14.41M↑ | -$15.70M↑ | -$19.39M | -$19.37M |
| Net Income | -$14.80M↓ | -$14.37M↑ | -$15.86M↑ | -$21.19M↓ | -$19.03M |
Peer Comparison
JNJUNHPFE
Fundamentals
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The compa...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$238.15M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-210.00%
Volume
Today's trading volume
384,394
Recent News
ImmunityBio (IBRX) Moves 11.8% Higher: Will This Strength Last?
ImmunityBio (IBRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
June 2026 Penny Stocks To Watch For Potential Growth
Over the last 7 days, the market has remained flat, but it is up 24% over the past year, with earnings expected to grow by 19% per annum over the next few years. For investors willing to explore beyond well-known stocks, penny stocks — often representing smaller or newer companies — can present intriguing opportunities. Despite being a somewhat outdated term, penny stocks remain a relevant investment area for those seeking potential growth and financial resilience in lesser-known companies.
INDV and the Shift to Long-Acting Opioid Use Disorder Care in 2026
Long-acting injectable adoption remains low, but Indivior's market position, payer access and consumer campaign could help drive growth into 2026.
Is Indivior Stock a Buy After Higher 2026 Guidance?
Indivior raised 2026 guidance after strong Q1 results, but investors are watching whether Sublocade growth and margin gains can sustain momentum.
INDV Stock: What Sublocade Growth Signals for 2026
Sublocade is powering Indivior's growth with record patient starts, rising volumes and a stable market share, setting up key demand tests for 2026.